tiprankstipranks
Advertisement
Advertisement

CRMD Stock Latest News

Federal Circuit Upholds CorMedix MINOCIN Patent Protection
Company AnnouncementsFederal Circuit Upholds CorMedix MINOCIN Patent Protection
4d ago
8K
CRMD
CorMedix announces United States Court of Appeals affirms patent judgements
PremiumThe Fly
CorMedix announces United States Court of Appeals affirms patent judgements
4d ago
CRMD
Cormedix Earnings Call Highlights Surging Growth, New Risks
PremiumCompany Announcements
Cormedix Earnings Call Highlights Surging Growth, New Risks
23d ago
CRMD
Cormedix Earnings Call Highlights Growth, Raises Outlook
PremiumCompany Announcements
Cormedix Earnings Call Highlights Growth, Raises Outlook
28d ago
CRMD
Analyst Reiterates Buy on Cormedix, Maintains Unchanged $13 Price Target Amid Strengthening Commercial Execution and Pipeline Prospects
PremiumRatings
Analyst Reiterates Buy on Cormedix, Maintains Unchanged $13 Price Target Amid Strengthening Commercial Execution and Pipeline Prospects
28d ago
CRMD
3 Low P/E Stocks with Over 40% Upside
PremiumMarket News3 Low P/E Stocks with Over 40% Upside
29d ago
CRMD
OPRA
CorMedix reports Q1 EPS 43c, consensus 33c
Premium
The Fly
CorMedix reports Q1 EPS 43c, consensus 33c
29d ago
CRMD
CorMedix raises FY26 revenue view to $325M-$345M from $300M-$320M
Premium
The Fly
CorMedix raises FY26 revenue view to $325M-$345M from $300M-$320M
29d ago
CRMD
CRMD Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-Earnings
CRMD Earnings Report this Week: Is It a Buy, Ahead of Earnings?
1M ago
CRMD
3 Best Cheap Stocks Under $10 Worth Watching in May 2026
PremiumMarket News
3 Best Cheap Stocks Under $10 Worth Watching in May 2026
1M ago
ACHR
CRMD
Citizens healthcare analysts hold an analyst/industry conference call
PremiumThe Fly
Citizens healthcare analysts hold an analyst/industry conference call
1M ago
CRMD
CorMedix price target raised to $14 from $13 at RBC Capital
PremiumThe Fly
CorMedix price target raised to $14 from $13 at RBC Capital
1M ago
CRMD
Buy Rating Reiterated on REZZAYO Trial Strength and Safety Profile; $13 Price Target Maintained
PremiumRatingsBuy Rating Reiterated on REZZAYO Trial Strength and Safety Profile; $13 Price Target Maintained
1M ago
CRMD
CorMedix Reports Positive Phase III REZZAYO Prophylaxis Results
Premium
Company Announcements
CorMedix Reports Positive Phase III REZZAYO Prophylaxis Results
2M ago
8K
CRMD
CorMedix announces ReSPECT clinical trial met primary endpoint
Premium
The Fly
CorMedix announces ReSPECT clinical trial met primary endpoint
2M ago
CRMD
3 ‘Strong Buy’ Low P/E Stocks with Over 40% Upside
PremiumMarket News
3 ‘Strong Buy’ Low P/E Stocks with Over 40% Upside
2M ago
GEO
CRMD
Cormedix: Undervalued Biotech with Differentiated Lead Asset and Attractive Risk‑Reward Justifying a Buy Rating
PremiumRatings
Cormedix: Undervalued Biotech with Differentiated Lead Asset and Attractive Risk‑Reward Justifying a Buy Rating
2M ago
CRMD
Cormedix Earnings Call: Peak DEFENCATH, Tough Road Ahead
PremiumCompany Announcements
Cormedix Earnings Call: Peak DEFENCATH, Tough Road Ahead
3M ago
CRMD
CorMedix Reaffirms DefenCath 2027 Sales and Outlook
PremiumCompany Announcements
CorMedix Reaffirms DefenCath 2027 Sales and Outlook
3M ago
8K
CRMD
CorMedix affirms FY26 revenue view of $300M-$320M, consensus $308.7M
PremiumThe FlyCorMedix affirms FY26 revenue view of $300M-$320M, consensus $308.7M
3M ago
CRMD
CorMedix price target lowered to $13 from $15 at Leerink
Premium
The Fly
CorMedix price target lowered to $13 from $15 at Leerink
3M ago
CRMD
Buy Rating Maintained as Long-Term Rezzayo Upside Remains Underappreciated Despite Near-Term Weakness
Premium
Ratings
Buy Rating Maintained as Long-Term Rezzayo Upside Remains Underappreciated Despite Near-Term Weakness
3M ago
CRMD

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >